keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer and adjuvance

keyword
https://www.readbyqxmd.com/read/29244528/phase-iii-randomized-study-of-dual-human-epidermal-growth-factor-receptor-2-her2-blockade-with-lapatinib-plus-trastuzumab-in-combination-with-an-aromatase-inhibitor-in-postmenopausal-women-with-her2-positive-hormone-receptor-positive-metastatic-breast-cancer
#1
Stephen R D Johnston, Roberto Hegg, Seock-Ah Im, In Hae Park, Olga Burdaeva, Galina Kurteva, Michael F Press, Sergei Tjulandin, Hiroji Iwata, Sergio D Simon, Sarah Kenny, Severine Sarp, Miguel A Izquierdo, Lisa S Williams, William J Gradishar
Purpose Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy...
December 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29243989/clinical-application-of-detecting-21-gene-recurrence-score-in-predicating-prognosis-and-therapy-response-of-patients-with-breast-cancer-from-two-medical-centers
#2
Guodong Xiao, Jinying Meng, Jing Zhang, Gang Li, Ning Du, Sida Qin, Jichang Wang, Chongwen Xu, Hong Ren, Shou-Ching Tang, Xin Sun
To determine the most suitable strategy in treating patients with invasive breast cancer from Northwest China. Lower recurrence score (RS) correlated with lower recurrence ratio. Patients having a medium-high 21-gene RS who received adjuvant therapy presented lower recurrence risk. Younger patients having RS results (⩾31) tended to accept adjuvant therapy more often, however, those having intermediate RS results were inclined to wait and did not receive chemotherapy. These results suggested that RS-based precision medicine will allow individualized diagnosis and treatment, resulting in better outcomes and preserved medical resources...
November 26, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/29243107/impact-of-geriatric-assessment-for-the-therapeutic-decision-making-of-breast-cancer-results-of-a-french-survey-afsos-and-sofog-collaborative-work
#3
Claire Falandry, Ivan Krakowski, Hervé Curé, Elisabeth Carola, Pierre Soubeyran, Olivier Guérin, Hélène Gaudin, Gilles Freyer
BACKGROUND: Cancer management in the elderly is often considered as suboptimal, highly variable, and rarely evidence-based. Data are needed to understand decision-making processes in this population. MATERIALS AND METHODS: A survey was performed in France to describe decision-making in gynaecologic patients over 70. It followed a three-step method: (1) 101 representative physicians questioned about treatment decision criteria; (2) simplified individual data were collected; (3) as well as detailed data patients receiving chemotherapy...
December 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29242516/mronj-risk-of-adjuvant-bisphosphonates-in-early-stage-breast-cancer
#4
V Patel, J Mansi, S Ghosh, J Kwok, M Burke, D Reilly, N Nizarali, C Sproat, K Chia
Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates...
December 15, 2017: British Dental Journal
https://www.readbyqxmd.com/read/29242041/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast-cancer-meta-analysis-of-individual-patient-data-from-ten-randomised-trials
#5
(no author information available yet)
BACKGROUND: Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. METHODS: We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively...
December 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29241890/value-of-information-analysis-of-multiparameter-tests-for-chemotherapy-in-early-breast-cancer-the-optima-prelim-trial
#6
Peter S Hall, Alison Smith, Claire Hulme, Armando Vargas-Palacios, Andreas Makris, Luke Hughes-Davies, Janet A Dunn, John M S Bartlett, David A Cameron, Andrea Marshall, Amy Campbell, Iain R Macpherson, Dan Rea, Adele Francis, Helena Earl, Adrienne Morgan, Robert C Stein, Christopher McCabe
BACKGROUND: Precision medicine is heralded as offering more effective treatments to smaller targeted patient populations. In breast cancer, adjuvant chemotherapy is standard for patients considered as high-risk after surgery. Molecular tests may identify patients who can safely avoid chemotherapy. OBJECTIVES: To use economic analysis before a large-scale clinical trial of molecular testing to confirm the value of the trial and help prioritize between candidate tests as randomized comparators...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29241676/breast-cancer-and-synchronous-multiple-myeloma-as-a-diagnostic-challenge-case-report-and-review-of-literature
#7
Marcin Sokołowski, Grzegorz Mazur, Aleksandra Butrym
Multiple myeloma is a hematological malignancy, which sometimes creates difficulties in diagnosis, based on the presence of monoclonal protein in serum/urine and plasmocyte infiltration in the bone marrow, and on the other hand, synchronous cancers are also a diagnostic challenge. We present a case report of a patient with concurrent breast cancer and multiple myeloma. A 68-year-old woman was admitted to the hospital with diagnosis of left breast cancer in first stage of the disease. In the past, she had had several episodes of thrombocytopenia, leucocytosis, and mild anaemia, which were followed by hematologist in outpatient setting...
November 22, 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/29239836/determinants-of-weight-gain-during-adjuvant-endocrine-therapy-and-association-of-such-weight-gain-with-recurrence-in-long-term-breast-cancer-survivors
#8
Akshara Raghavendra, Arup K Sinha, Janeiro Valle, Yu Shen, Debu Tripathy, Carlos H Barcenas
BACKGROUND: Weight gain is a negative prognostic factor in breast cancer (BC) patients. The risk factors for weight gain during adjuvant endocrine therapy (ET) and the extent to which such weight gain is associated with disease recurrence remain unclear. PATIENTS AND METHODS: We retrospectively identified a cohort of women with a diagnosis of stage I-III, hormone receptor-positive, human epidermal growth factor receptor 2-negative BC from January 1997 to August 2008, who had received initial treatment at the MD Anderson Cancer Center, had completed 5 years of ET, and had remained free of locoregional or distant relapse or contralateral BC for ≥ 5 years after diagnosis...
November 9, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29238654/primary-endocrine-therapy-in-older-women-with-breast-cancer
#9
REVIEW
R M C Pepping, J E A Portielje, W van de Water, N A de Glas
Purpose of Review: Breast cancer incidence increases with age. In recent years, primary endocrine therapy has been increasingly used as a treatment option for frail elderly women with breast cancer, although surgery is still the guideline-recommended treatment. In this review, we discuss the evidence for primary endocrine therapy versus surgical treatment in older women with early breast cancer. Recent Findings: Both randomised controlled trials and recent observational studies showed a favourable progression-free survival but not overall survival for surgery plus adjuvant endocrine therapy versus primary endocrine therapy...
2017: Current Geriatrics Reports
https://www.readbyqxmd.com/read/29237035/adjuvant-chemotherapy-for-er-breast-cancer-a-sea-change-is-underway
#10
Philip D Poorvu, Eric P Winer
No abstract text is available yet for this article.
December 11, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29236294/acute-myeloid-leukemia-and-myelodysplastic-syndrome-after-adjuvant-chemotherapy-a-population-based-study-among-older-breast-cancer-patients
#11
Aron S Rosenstock, Jiangong Niu, Sharon H Giordano, Hui Zhao, Antonio C Wolff, Mariana Chavez-MacGregor
BACKGROUND: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancer patients and to further define the risk of individual chemotherapy regimens. METHODS: Patients diagnosed with stage I to III breast cancer from 2003 to 2009 were identified in the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked databases...
December 13, 2017: Cancer
https://www.readbyqxmd.com/read/29236174/oncotype-dx%C3%A2-in-breast-cancer-patients-clinical-experience-outcome-and-follow-up-a-case-control-study
#12
Michelle G Rath, Lorenz Uhlmann, Marita Fiedler, Joerg Heil, Michael Golatta, Christine Dinkic, Andre Hennigs, Sarah Schott, Veronika Ernst, Thorsten Koch, Christof Sohn, Cosima Brucker, Joachim Rom
PURPOSE: Breast cancer is the leading cause of death from cancer in women and the most common cancer in the world [1]. To date, many patients with estrogen-receptor-positive (ER+) breast cancer are overtreated with chemotherapy when the rationale for adjuvant chemotherapy is based on clinicopathologic parameters. Different studies were able to demonstrate that a 21-gene expression assay (Oncotype DX® Genomic Health, Redwood City, CA) can predict the benefit from adjuvant chemotherapy in ER+ breast cancers [2, 3] and provide additional prognostic information independent of clinicopathological features [4]...
December 13, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29235043/effects-of-physical-exercise-on-markers-of-inflammation-in-breast-cancer-patients-during-adjuvant-chemotherapy
#13
Jonna K van Vulpen, Martina E Schmidt, Miranda J Velthuis, Joachim Wiskemann, Andreas Schneeweiss, Roel C H Vermeulen, Nina Habermann, Cornelia M Ulrich, Petra H M Peeters, Elsken van der Wall, Anne M May, Karen Steindorf
PURPOSE: Exercise has been shown to reduce fatigue during cancer treatment. Hypothesized mechanisms include inflammatory pathways. Therefore, we investigated effects of exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy. METHODS: We pooled data from two randomized controlled exercise intervention trials with breast cancer patients during adjuvant chemotherapy (n = 130), which had previously shown beneficial effects of exercise on fatigue...
December 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29234899/correction-to-ten-year-results-of-accelerated-hypofractionated-adjuvant-whole-breast-radiation-with-concomitant-boost-to-the-lumpectomy-cavity-after-conserving-surgery-for-early-breast-cancer
#14
Domenico Cante, Edoardo Petrucci, Piera Sciacero, Cristina Piva, Silvia Ferrario, Silvia Bagnera, Sebastiano Patania, Guido Mondini, Massimo Pasquino, Valeria Casanova Borca, Giorgio Vellani, Maria Rosa La Porta, Pierfrancesco Franco
An error inadvertently occurred in the discussion of the original publication when citing the local relapse rates of the EORTC 22881-10882 trial ('boost vs no boost trial').
December 12, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29234720/radiation-induced-circumscribed-superficial-morphea-after-brachytherapy-for-endometrial-adenocarcinoma
#15
Apoorva Trivedi, Corey M DeWitt, Laura McGevna
Radiation-induced morphea (RIM) is a rare and underrecognized complication of radiation therapy that most commonly occurs in women after treatment for breast cancer. Although not fully understood, RIM is hypothesized to arise from an increase in cytokines that stimulate collagen production and extracellular matrix formation. Most documented cases of RIM occur 1 year after radiation therapy and are localized to areas that were treated for breast cancer. We report on a case of a female patient with stage IB endometrial adenocarcinoma who was treated with 24 Gray of adjuvant brachytherapy...
December 2017: International Journal of Women's Dermatology
https://www.readbyqxmd.com/read/29234591/reproductive-hormone-analyses-and-effects-of-adjuvant-zoledronic-acid-in-early-breast-cancer-an-azure-big-01-04-sub-study
#16
Caroline Wilson, Samantha Hinsley, Helen Marshall, David Cameron, Richard Bell, David Dodwell, Robert E Coleman
Purpose: Adjuvant bisphosphonates have been shown to improve disease outcomes in early breast cancer in women who are postmenopausal at the start of treatment. We explored the influence of pretreatment serum levels of reproductive hormones in the hypothalamic-pituitary-gonadal (HPG) axis from a subset of patients included in the AZURE trial to investigate their impact on disease recurrence and whether reproductive hormone measurements are of value in selecting patients for treatment with adjuvant zoledronic acid...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29234362/chinese-herbal-medicine-as-an-adjunctive-therapy-ameliorated-the-incidence-of-chronic-hepatitis-in-patients-with-breast-cancer-a-nationwide-population-based-cohort-study
#17
Kuo-Chin Huang, Hung-Rong Yen, Jen-Huai Chiang, Yuan-Chih Su, Mao-Feng Sun, Hen-Hong Chang, Sheng-Teng Huang
We conducted a National Health Insurance Research Database-based Taiwanese nationwide population-based cohort study to evaluate whether Chinese herbal medicine (CHM) treatment decreased the incidence of chronic hepatitis in breast cancer patients receiving chemotherapy and/or radiotherapy. A total of 81171 patients were diagnosed with breast cancer within the defined study period. After randomly equal matching, data from 13856 patients were analyzed. Hazard ratios of incidence rate of chronic hepatitis were used to determine the influence and therapeutic potential of CHM in patients with breast cancer...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/29234253/evaluation-of-sentinel-lymph-node-biopsy-and-axillary-lymph-node-dissection-for-breast-cancer-treatment-concepts-a-retrospective-study-of-1-214-breast-cancer-patients
#18
Roland G Stein, Roland Fricker, Thomas Rink, Hartmut Fitz, Sebastian Blasius, Joachim Diessner, Sebastian F M Häusler, Tanja N Stüber, Victoria Andreas, Achim Wöckel, Thomas Müller
Background: Most breast cancer patients require lumpectomy with axillary sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). The ACOSOG Z0011-trial failed to detect significant effects of ALND on disease-free and overall survival among patients with limited sentinel lymph node (SLN) metastases. Intense dose-dense chemotherapy and supraclavicular fossa radiation (SFR) are indicated for patients with extensive axillary metastases. In this multicentered study, we investigated the relevance of ALND after positive SLNB to determine adequate adjuvant therapy...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29233548/the-impact-of-actual-body-weight-based-chemotherapy-dosing-and-body-size-on-adverse-events-and-outcome-in-older-patients-with-breast-cancer-results-from-cancer-and-leukemia-group-b-calgb-trial-49907-alliance-a151436
#19
Vicki A Morrison, Linda McCall, Hyman B Muss, Aminah Jatoi, Harvey J Cohen, Constance T Cirrincione, Jennifer A Ligibel, Jacqueline M Lafky, Arti Hurria
OBJECTIVE: Actual weight-based (AWB) chemotherapy dosing is recommended for obese patients in the 2012 ASCO Clinical Practice Guideline. CALGB 49907, which utilized ABW-based adjuvant chemotherapy dosing, was a phase 3 trial in women age≥65years with early stage breast cancer, providing the opportunity to examine impact of such dosing on toxicities and outcome in older patients with breast cancer. MATERIALS AND METHODS: Adverse event data were available for 615 of 633 enrolled patients...
December 7, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29232804/lymphovascular-invasion-as-a-negative-prognostic-factor-for-triple-negative-breast-cancer-after-surgery
#20
Ki Jung Ahn, Jisun Park, Yunseon Choi
Purpose: This study aimed to evaluate the prognostic effects of lymphovascular invasion (LVI) in triple-negative breast cancer (TNBC) patients who underwent surgical resection. Materials and Methods: A total of 63 non-metastatic TNBC patients who underwent surgical resection were retrospectively investigated from 2007 to 2016 in Inje University Busan Paik Hospital. Pathological tests revealed that 12 patients (19.0%) had LVI. Approximately 61.9% (n = 39) of the patients' samples stained positive for p53...
December 15, 2017: Radiation Oncology Journal
keyword
keyword
118673
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"